Triangle Securities Wealth Management Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Triangle Securities Wealth Management lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 30.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,814 shares of the company's stock after buying an additional 1,120 shares during the quarter. Eli Lilly and Company comprises 1.0% of Triangle Securities Wealth Management's investment portfolio, making the stock its 26th biggest position. Triangle Securities Wealth Management's holdings in Eli Lilly and Company were worth $3,976,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Heritage Family Offices LLP boosted its holdings in shares of Eli Lilly and Company by 8.9% in the first quarter. Heritage Family Offices LLP now owns 2,138 shares of the company's stock worth $1,765,000 after acquiring an additional 174 shares during the period. Level Financial Advisors boosted its stake in Eli Lilly and Company by 8.7% in the 1st quarter. Level Financial Advisors now owns 460 shares of the company's stock worth $380,000 after purchasing an additional 37 shares during the period. First Financial Corp IN grew its holdings in Eli Lilly and Company by 0.9% during the 1st quarter. First Financial Corp IN now owns 4,545 shares of the company's stock valued at $3,754,000 after buying an additional 41 shares in the last quarter. Romano Brothers AND Company increased its position in shares of Eli Lilly and Company by 9.6% during the first quarter. Romano Brothers AND Company now owns 6,050 shares of the company's stock valued at $4,997,000 after buying an additional 531 shares during the period. Finally, Bremer Bank National Association lifted its holdings in shares of Eli Lilly and Company by 4.3% in the first quarter. Bremer Bank National Association now owns 13,339 shares of the company's stock worth $11,017,000 after buying an additional 554 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 0.1%

LLY stock traded down $0.71 during midday trading on Thursday, hitting $765.13. The company had a trading volume of 3,632,853 shares, compared to its average volume of 3,644,545. The stock has a market cap of $725.14 billion, a price-to-earnings ratio of 65.34, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock's 50 day moving average price is $772.75 and its 200 day moving average price is $799.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company's quarterly revenue was up 45.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.78%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on LLY shares. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. UBS Group lowered their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective for the company. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, May 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.